Interesting update from NCI's "exceptional responder" initiative
Why is it that patients with apparently similar profiles not infrequently have very different responses in oncology clinical trials? This vexing question led NCI in 2014 to launch a "phenotype to genotype" trial initiative - the exceptional responder study. On July 6th 2017 there was an interesting update to this work on the NCI's blog. Worth a read.
Regional Team Head TSS Hematology Oncology EU at IQVIA
7 年In the practice, a subset –still small- of metastatic cancer patients achieve a complete response with the standard treatment. Long-lasting responders and those can be considered cured could be categorized as different subgroups of responders. Thus, one can hypothesize that short responders to the treatment, long-lasting and cured cancer patients may have different tumor predictive biomarker and immune competence profiles and balance, whereas cured patients ahould be the representation of favorable predictive tumor biomarkers together with an efficient post-cancer immune competent machinery. There is a significant advance with the early but behind for the later to complement our understanding about the cure of cancer...
CEO @ Ovum Health * Gen-AI Health Care Leader * Venture-Backed Mom * Policy Maker * Author *
7 年Am dying to run the data on genteract! How can I get into that conversation? (I owe you a phone call!!)